stockrowVir Biotechnology, Inc.
VIRVir Biotechnology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $68.6 million, down 7.61% from fiscal 2024.
- Revenue
- −178.3%
- EPS
- +51.4%
- Free cash flow
- +36.8%
Quarter to September 2026, against a year earlier
Follow VIR
Alert me
Vir Biotechnology, Inc. (VIR) Gross margin
Vir Biotechnology, Inc.'s gross margin over the twelve months to 30 September 2026 was 100.0%, up 0.0 percentage points from fiscal 2025 (100.0%). Over the past ten years it has ranged from 90.9% (fiscal 2022) to 100.0% (fiscal 2020); the current reading is higher than 56% of that period. That is above the Biotechnology industry median of 68.8% and above the Healthcare sector median of 55.5%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 100.0% | 1.10 |
| FY2024 | 98.9% | 2.07 |
| FY2023 | 96.8% | 5.85 |
| FY2022 | 90.9% | (3.05) |
| FY2021 | 94.0% | (6.01) |
| FY2020 | 100.0% | 0.00 |
| FY2019 | 100.0% | 0.00 |
| FY2018 | 100.0% | 0.00 |
| FY2017 | 100.0% | — |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 100.0% | 0.00 |
| Jun 2026 | 100.0% | 0.00 |
| Mar 2026 | 100.0% | 0.04 |
| Dec 2025 | 100.0% | (4.62) |
| 28 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| IMNM Immunome, Inc. compare | 100.0% |
| NAMS NewAmsterdam Pharma Company N.V. compare | 100.0% |
| VIR Vir Biotechnology, Inc. | 100.0% |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 89.8% |
| ZYME Zymeworks Inc. compare | 51.4% |
| RXRX Recursion Pharmaceuticals, Inc. compare | 29.2% |
| BHVN Biohaven Ltd. compare | 0.00% |
| REPL Replimune Group, Inc. compare | 0.00% |
| TRAX First Tracks Biotherapeutics, Inc. compare | — |
| Biotechnology industry median | 68.8% |
| Healthcare sector median | 55.5% |
| Market median | 47.0% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on VIR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement